Complejo Asistencial de Segovia-ko ikertzaileekin lankidetzan egindako argitalpenak (217)

2024

  1. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1596-1604

  3. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study

    The Lancet Microbe, Vol. 4, Núm. 6, pp. e431-e441

  4. Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets

    American Journal of Hematology

  5. Physical activity patterns in type 1 diabetes in Spain: The SED1 study

    BMC Sports Science, Medicine and Rehabilitation, Vol. 15, Núm. 1

  6. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  7. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

  3. Multiple myeloma with chronic kidney disease dependent on peritoneal dialysis and autologous stem cell transplant

    Nefrologia

  4. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  5. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  3. Clinical characteristics of chronic kidney disease (no dialysis) in nonagenarians

    Revista Espanola de Geriatria y Gerontologia, Vol. 56, Núm. 2, pp. 119-120

  4. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia

    Haematologica, Vol. 106, Núm. 8, pp. 2215-2223

  5. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

    British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530

  6. Lung cancer patients with COVID-19 in Spain: GRAVID study

    Lung Cancer, Vol. 157, pp. 109-115

2020

  1. About of onco-nephrology: Chronic kidney disease in oncology patients not hospitalised

    Nefrologia